These molecular changes may relatively explain why a double β-catenin/NHERF1-inhibitory strategy may be a fruitful mechanism-based strategy to augment apoptotic death of CRC cells refractory to Wnt/β-catenin-targeted therapeutics [3, 5, 6]. Here, NHERF1 is linked to colorectal carcinoma.